Cure Research for Kidney disease

/Home/Complications of Leukemia/Leukemia and Kidney Failure/Leukemia and Kidney Failure Research

Cure Research for Kidney disease
Wrongdiagnosis.com

Last Update: 17 March, 2009

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), through its Division of Kidney, Urologic, and Hematologic Diseases, supports several programs and studies devoted to improving treatment for patients with progressive kidney disease and end-stage kidney failure (sometimes called end-stage renal disease, or ESRD), including patients on hemodialysis:

* The End-Stage Renal Disease Program. This program promotes research to reduce medical problems from bone, blood, nervous system, metabolic, gastrointestinal, cardiovascular, and endocrine abnormalities in end-stage kidney failure and to improve the effectiveness of dialysis and transplantation. The research focuses on reuse of hemodialysis membranes and on using alternative dialyzer sterilization methods; on devising more efficient, biocompatible membranes; on refining high-flux hemodialysis; and on developing criteria for dialysis adequacy. The program also seeks to increase kidney graft and patient survival and to maximize quality of life.
* The HEMO Study. This multicenter clinical trial is testing whether a higher hemodialysis dose and/or high-flux membranes will reduce patient mortality (death) and morbidity (medical problems).
* The U.S. Renal Data System (USRDS).This national data system collects, analyzes, and distributes information about the use of dialysis and transplantation to treat kidney failure in the United States. The USRDS is funded directly by the NIDDK in conjunction with the Health Care Financing Administration. The USRDS publishes an Annual Data Report, which characterizes the total population of people being treated for kidney failure; reports on incidence, prevalence, mortality rates, and trends over time; and develops data on the effects of various treatment modalities. The report also helps identify problems and opportunities for more focused special studies of renal research issues.
* The Hemodialysis Vascular Access Clinical Trials Consortium will conduct a series of multicenter, randomized, placebo-controlled clinical trials of drug therapies
to reduce the failure and complication rate of arteriovenous grafts and fistulas in hemodialysis. Recently developed antithrombotic agents and drugs to inhibit cytokines may be evaluated in these large clinical trials.

(Source: excerpt from Anemia in Kidney Disease and Dialysis: NIDDK)

Information provided on this site is for informational purposes only; it is not intended as a substitute for advice from your own medical team. The information on this site is not to be used for diagnosing or treating any health concerns you may have - please contact your physician or health care professional for all your medical needs.

Copyright © 2009 Health Grades Inc.